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Abstract
Tumor necrosis factor receptor 1 (TNFR1)-associated death domain protein (TRADD) is an important adaptor in TNFR1
signaling and has an essential role in nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) activation
and survival signaling. Increased expression of TRADD is sufficient to activate NF-κB. Recent studies have highlighted
the importance of NF-κB activation as a key pathogenic mechanism in glioblastoma multiforme (GBM), the most
common primary malignant brain tumor in adults. We examined the expression of TRADD by immunohistochemistry
(IHC) and find that TRADD is commonly expressed at high levels in GBM and is detected in both cytoplasmic and
nuclear distribution. Cytoplasmic IHC TRADD scoring is significantly associated with worse progression-free survival
(PFS) both in univariate and multivariate analysis but is not associated with overall survival (n = 43 GBMs). PFS is a
marker for responsiveness to treatment. We propose that TRADD-mediated NF-κB activation confers chemo-
resistance and thus a worse PFS in GBM. Consistent with the effect on PFS, silencing TRADD in glioma cells results
in decreased NF-κB activity, decreased proliferation of cells, and increased sensitivity to temozolomide. TRADD
expression is common in glioma-initiating cells. Importantly, silencing TRADD in GBM-initiating stem cell cultures
results in decreased viability of stem cells, suggesting that TRADD may be required for maintenance of GBM stem
cell populations. Thus, our study suggests that increased expression of cytoplasmic TRADD is both an important
biomarker and a key driver of NF-κB activation in GBM and supports an oncogenic role for TRADD in GBM.
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Introduction
Tumor necrosis factor receptor 1 (TNFR1)-associated death domain
protein (TRADD) is an important component of the TNFR1 signal-
ing network [1,2]. It plays a key role in TNFR1-induced nuclear
factor kappa-light-chain-enhancer of activated B cells (NF-κB) acti-
vation and cell survival. Increased expression of TRADD is known to
activate NF-κB [1]. In common with other members of the TNF
superfamily, TRADD may also induce apoptosis, depending on
the cellular context [3]. TRADD also has a role in innate immunity
and has been implicated in toll-like receptor 3 and toll-like receptor
4 signaling [4]. TRADD functions as an adaptor and is involved in
assembly of a signaling platform at TNFR1 that includes other proteins
such as TNF receptor–associated factor 2 and receptor interacting
protein 1 (RIP1) [5]. Activation of TNFR1 has been shown to result
in the formation of sequential signaling complexes, including a
membrane-associated complex that mediates survival and includes
TRADD and a subsequent cytosolic death complex composed of
TRADD, RIP1, and Fas-associated protein with death domain [6].
Although TRADD has been considered a cytoplasmic protein, it can
shuttle between the cytoplasm and the nucleus and has both a putative
nuclear localization signal and a putative nuclear export signal [7–9]. In
the nucleus, TRADDmay interact with key regulatory proteins and/or
influence transcription of key genes [8,9].
Although TRADD has been investigated intensively in inflamma-
tory and immune signaling, much less is known about its role in cancer.
On the basis of TRADD’s role in proinflammatory signaling and the
key role of inflammation in the pathogenesis of cancer, an oncogenic
role for TRADD is plausible. However, TRADD also has a role in cell
death and, furthermore, is located in a chromosomal region (16q22.1)
showing frequent loss of heterozygosity in various cancers [8,10],
suggesting a tumor suppressive role for TRADD. A recent study has
shown that TRADD plays a tumor suppressive role in an experimental
model of skin cancer in mice and suggested that low levels of TRADD
conferred a worse prognosis [8].
Glioblastoma multiforme (GBM) is the most common primary
malignant tumor of the central nervous system in adults [11]. The
treatment of GBM remains an intractable problem [12]. The Cancer
Genome Atlas has provided a comprehensive picture of genetic abnor-
malities in GBM [13–17]. The molecular pathogenesis of glioma is
thought to involve multiple genetic alterations that result in aberrant
activity of pathways involved in proliferation, cell cycle regulation,
and apoptosis [16–19]. The genetic changes detected frequently in
primary GBM include INK4A loss, epidermal growth factor receptor
(EGFR) amplification and mutation, phosphatase and tensin homolog
loss, and mouse double minute 2 homolog amplification, among other
abnormalities. TRADD is reported to be highly expressed in the
mesenchymal subtype of GBM along with other NF-κB genes such
as RelB [16].
Aberrant NF-κB activation is widespread in cancer [20,21]. NF-κB
has important roles in cell viability and cell cycle progression and influ-
ences proliferation of cancer cells and resistance to treatment [22,23].
There is also an extensive cross talk between NF-κB activation and
oncogenic and tumor suppressor signaling pathways [24,25]. Recent
studies suggest that NF-κB activation is an important contributor to
the malignant phenotype in GBM [12]. It has been suggested that
two major pathways activate NF-κB in GBM [26]. First, EGFR gene
amplification and aberrant EGFR gene amplification are detected
in 40% to 50% of GBMs and increased EGFR signaling is well
documented to activate NF-κB [27–30]. Second, NF-κB inhibitor α
(NFKBIA, which encodes IκBα) is commonly deleted in non–
EGFR-amplified GBMs resulting in NF-κB activation [26]. However,
additional pathways such as transforming growth factor β also activate
NF-κB in GBM [31]. Furthermore, other members of the TNFR/
NF-κB superfamily, such as A20, have also been implicated in main-
tenance of stem cells in GBM [32].
Gliomas are graded I to IV in order of increasing malignancy, and
GBM (grade IV) is the most malignant. TRADD is a key component
of the NF-κB signaling pathway and functions primarily as an adaptor.
Recent studies have demonstrated that NF-κB activation is common
in GBM and proposed aberrant EGFR signaling and IκBα deletion as
major mechanisms of NF-κB activation in GBM. However, additional
mechanisms are likely. For example, increased expression of compo-
nents of NF-κB pathway may also be sufficient for NF-κB activation.
We have previously shown that increased expression in RIP1 is sufficient
to induce NF-κB activation in glioma cells. Furthermore, high levels of
RIP1 are common in GBM and confer a worse prognosis [25].
In this study, we propose that increased TRADD expression is an
important mechanism of NF-κB activation in GBM. We show that
TRADD expression is robust in GBMs. Increased levels of cytoplasmic
TRADD results in a worse progression-free survival (PFS) in GBM
patients. Nuclear presence of TRADD has no effect on prognosis.
Consistent with the effect on PFS, silencing TRADD in glioma cells
results in decreased NF-κB activity, decreased proliferation of cells, and
increased sensitivity to temozolomide. Silencing TRADD in GBM
stem cell cultures results in decreased viability of cells, suggesting that
TRADD may be required for maintenance of GBM stem cell popu-
lations. Thus, our data suggest that cytoplasmic TRADD plays an
oncogenic role in GBM.
Materials and Methods
Antibodies, Reagents, and Western Blot
TRADD antibody was purchased fromNovus Biologicals (Littleton,
CO; Cat. No. NB-100-92112). IκBα and actin antibodies were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA). Phospho-
p65 and p65 antibodies were purchased from Cell Signaling Tech-
nology (Danvers, MA). Protein quantitation was performed using a
BIO-RAD kit (Hercules, CA). Western blot was performed according
to standard protocols.
Protein lysates were prepared for Western blot using a lysis buffer con-
taining 1% NP-40, 150 mM NaCl, 0.25 deoxycholate, 1 mM EGTA,
1 mM NaF, 50 mM Tris-HCl, 1 mM PMSF, 2 mM orthovanadate,
and a protease inhibitor cocktail.
RNA Interference
TRADD was silenced using lentiviral shRNA ready-to-use transduc-
tion particles from Santa Cruz Biotechnology (sc-36709-V, containing
three target-specific constructs) and puromycin selection according
to the manufacturer’s protocol. As a control, we used control (scram-
bled, non-sequence) shRNA lentiviral particles also from Santa Cruz
Biotechnology. TRADD silencing was confirmed with Western blot.
Luciferase Assays
TRADD-silenced or control shRNA cells were plated onto 24-well
dishes followed by transfection with an NF-κB–LUC reporter. A dual-
luciferase reporter assay system was used according to the instructions
of the manufacturer (Promega, Madison, WI). Firefly luciferase activ-
ity was measured in a luminometer and normalized on the basis of
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Renilla luciferase activity. Experiments were done in triplicate and
repeated twice.
Cell Proliferation Assays
5K cells were plated onto 24-well dishes. The cells were trypsinized,
analyzed by trypan blue exclusion for dead cells, and counted using
an automated cell counter after 72 hours of plating. At least three
independent experiments were done in triplicate.
3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium
Bromide (MTT) Conversion Assays
U251 control shRNA or TRADD-silenced cells were plated at 5K
per well in 96-well dishes. An MTT kit from Roche Applied Science
(Indianapolis, IN) was used according to themanufacturer’s instructions.
Primary Tumors/Immunohistochemistry
Informed consent was obtained and all studies were conducted
according to Institutional Review Board-approved protocols at the
University of Texas Southwestern Medical Center.
The TRADD antibody used was from Novus Biosciences (Cat.
No. NB100-92112; Novus Biologicals) and was used for bothWestern
blot and immunohistochemistry (IHC). We validated this antibody
in TRADD knockdown cells by Western blot. As can be seen in
Figure 4A, the TRADD signal is lost in cells when TRADD is knocked
down with siRNA. The antibody was developed for IHC in the
Neuropathology IHC Core at the University of Texas Southwestern
Medical Center. An isotype-matched control antibody was used as a
negative control.
Cores (1.5 mm) for tissue microarrays (TMAs) were punched
using a tissue microarrayer (Beecher Instruments, Sun Prairie, WI).
The donor blocks were formalin-fixed, paraffin-embedded tissue
blocks of human gliomas. TMA sections of human gliomas were
cut at 4-μm thickness and deparaffinized. For antigen retrieval,
the sections were heated for 30 minutes at 95°C in CC1 Solution
(Ventana Medical Systems, Tucson, AZ). The sections were exposed
to a rabbit polyclonal antibody to human and mouse TRADD
(NB100-92112; Novus Biologicals) at 1:100 dilution. The signal
was developed with the alkaline phosphatase–based ultraView uni-
versal detection system (Ventana Medical Systems). The chromogen
was ultraView DAB (Ventana Medical Systems). The immuno-
staining procedure was performed using the Benchmark XT automated
stainer (Ventana Medical Systems). The IHC staining intensity for
TRADDwas scored semiquantitatively. The final IHC score was derived
from IHC staining intensity multiplied by the percentage of tumor
cells showing positive staining as we have described previously [33].
Primary GBM cultures were generated directly from human tumor
specimens. A papain dissociation system was used to dissociate tumors.
Cells were then cultured in neurobasal medium supplemented with
B27 without vitamin A and with EGF (10 ng/ml) and basic fibroblast
growth factor (10 ng/ml), as described previously [34].
Annexin FACS
Annexin assay was done by using Annexin-V-FLUOS Staining
Kit (Roche Applied Science). Neurosphere cultures from TRADD-
silenced or control shRNA cells (1 × 106) or U251MG cells with
control shRNA or TRADD shRNA were plated onto six-well plates.
The cells were incubated for 25 minutes at room temperature with
propidium iodide and Annexin-V-FLUOS labeling solution in in-
cubation buffer (supplied by the manufacturer). Annexin and or
propidium iodide–positive cells were detected by flow cytometry.
TRADD silencing was confirmed by Western blot.
Statistical Analysis
Our data set contains 43 GBM patients with detailed clinical infor-
mation. All patients have received radiotherapy and chemotherapy.
The primary end point was PFS, defined as the time from the com-
pletion of surgery to tumor recurrence, death from any cause, or last
follow-up contact. We also studied overall survival (OS), defined as
the time from the completion of surgery to death or last follow-up
contact. To evaluate the association of TRADD levels with survival,
patients were divided into two equal-sized groups based on the median
of their IHC scorings. Survival curves for PFS and OS were examined
using the Kaplan-Meier method and were compared using log-rank
test. Univariate and multivariate survival analyses were performed using
Cox proportional hazards model. Multivariate models were adjusted
for age (in years, as a continuous variable), gender (male or female),
Karnofsky performance score (KPS; as a continuous variable), and
surgery (partial removal or complete removal).
Error bars represent the means ± SDs of three independent ex-
periments. All data were analyzed for significance using GraphPad
Prism 5.0 software, where P < .05 was considered statistically signifi-
cant. One-way analysis of variance (ANOVA) and two-tailed t test
were used to compare groups.
Results
TRADD Expression in GBM
Because TRADD plays a key role in NF-κB activation, we investi-
gated TRADD levels in GBM. TRADD expression was examined in
GBM TMAs. GBMs were assessed for the presence of TRADD in
nucleus and cytoplasm, and a semiquantitative TRADD score was
compiled using the intensity of staining as well as the number of stained
cells in each tumor. Nuclear as well as cytoplasmic staining was studied.
Figure 1 shows representative photomicrographs of TRADD IHC in
human GBMs on a TMA. Figure 1A shows strong cytoplasmic posi-
tivity for TRADD in a GBM, whereas Figure 1B shows strong nuclear
and moderate cytoplasmic positivity for TRADD in a second case of
GBM. Figure 1C shows absent to weak positivity for TRADD in
a third case of GBM. Figure 1D shows absent to weak positivity
for TRADD in an oligodendroglioma [World Health Organization
(WHO) grade II], a type of low-grade glioma. Figure 2 shows a rep-
resentative low-power photomicrograph of a TMA core from a human
GBM showing strong expression of TRADD.
Cytoplasmic TRADD Expression Confers a Worse
Prognosis in GBM
Next, we investigated whether TRADD expression influences prog-
nosis in GBM. Our data set contains 43 GBM patients with detailed
clinical information (Table W1). All patients received radiotherapy
and chemotherapy.
The primary end point was PFS, defined as the time from the com-
pletion of surgery to tumor recurrence, death from any cause, or last
follow-up contact. We also studied OS, defined as the time from the
completion of surgery to death or last follow-up contact. To evaluate
the association of TRADD levels with survival, patients were divided
into two equal-sized groups based on the median of their IHC scorings.
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Survival curves for PFS and OS were examined using the Kaplan-Meier
method and were compared using log-rank test. Univariate and multi-
variate survival analyses were performed using Cox proportional hazards
model [35]. Multivariate models were adjusted for age (in years, as a
continuous variable), gender (male or female), KPS (as a continuous
variable), and surgery (partial removal or complete removal).
Figure 1. Representative photomicrographs of TRADD IHC in human gliomas on a TMA. (A) Strong cytoplasmic positivity for TRADD in a
glioblastoma. (B) Strong nuclear and moderate cytoplasmic positivity for TRADD in a second case of glioblastoma. (C) Absent to weak
positivity for TRADD in a third case of glioblastoma. (D) Absent to weak positivity for TRADD in an oligodendroglioma (WHO grade II),
a type of low-grade glioma (IHC for TRADD with hematoxylin counterstain. Size bar, 50 μm. Original magnification, ×200).
Figure 2. A representative low-power photomicrograph of a TMA
core from a human glioblastoma showing strong expression of
TRADD (IHC for TRADD with hematoxylin counterstain. Scale bar,
100 μm).
Figure 3. Association of cytoplasmic TRADD level with PFS. To eval-
uate the association of TRADD levels with survival, patients were
divided into two equal-sized groups based on the median of their
IHC scorings. Survival curves for PFS were generated using the
Kaplan-Meier method and were compared using log-rank test. Uni-
variate analyses was performed using Cox proportional hazards
model (multivariate analysis is described in Table 1). Dashed line
represents high cytoplasmic TRADD, while solid line represents
low cytoplasmic TRADD.
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The cytoplasmic TRADD level showed significant association with
PFS. The group with high IHC scoring had significantly worse sur-
vival outcomes than the low IHC group: hazard ratio (HR) = 2.13,
95% confidence interval (CI) = 1.05 to 4.32, P = .0324 (Figure 3).
Multivariate analysis adjusting for preselected significant prognostic fac-
tors showed that the IHC scoring is an independent prognostic factor
for PFS: HR = 2.471, 95% CI = 1.143 to 5.341, P = .021 (Table 1).
When we examined the association between the cytoplasmic TRADD
level and patients’ OS, we found no significant difference in OS be-
tween high and low IHC scoring groups: HR = 1.034, 95% CI =
0.489 to 2.186, P = .884. It should be noted that no association be-
tween nuclear TRADD IHC and OS or PFS was detected.
Silencing TRADD Inhibits NF-κB Activation
To examine the role of TRADD in an experimental cell culture
model of glioma, we used the established GBM cell line U251MG
and undertook to stably silence TRADD in these cells using lentiviral
shRNA. Two clones with stably silenced TRADD were identified
(Figure 4A) and designated as clones 15 and 26. As a control, we
use scrambled (non-sequence) shRNA. Since TRADD is involved in
NF-κB activation, we tested whether silencing TRADD in these cells
influenced TNF-α–induced NF-κB activation. NF-κB subunits are
normally sequestered in the cytoplasm by IκBα. Addition of TNF-α
to cells results in degradation of IκBα allowing NF-κB subunits
to translocate to the nucleus and initiate gene transcription. Thus,
we examined the degradation of IκBα by Western blot as a readout
for NF-κB activation. As can be seen in Figure 4B, while IκBα is de-
graded in response to TNF-α stimulation in control shRNA cells,
we do not detect degradation of IκBα in TRADD-silenced clones
(Figure 4, C and D). Furthermore, we examined the effect of TRADD
silencing on TNF-α–induced NF-κB transcriptional activity by using
an NF-κB responsive luciferase reporter assay. Silencing of TRADD
inhibited TNF-α–induced NF-κB transcriptional activity as is shown
in Figure 4E . In addition, phosphorylation of the p65 subunit is
impaired in TRADD-silenced cells (Figure 4F ). Finally, induction
of an NF-κB target gene [interleukin-8 (IL-8)] is also impaired in
TRADD-silenced cells (Figure 4G).
A Role for TRADD in Proliferation of Glioma Cells and
in Resistance to Temozolomide
NF-κB has important roles in cell viability and cell cycle progres-
sion and influences proliferation of cancer cells and resistance to treat-
ment. Thus, we examined whether silencing TRADD influenced the
viability/proliferation of cells. We examined the viability/proliferation
of U251 control shRNA and TRADD-silenced clones 15 and 26 in
monolayer culture using cell counting and an MTT assay. As can
be seen in Figure 5, A and B, the clones with stably silenced TRADD
exhibited decreased proliferation of cells compared to control (scram-
bled) shRNA-expressing cells. TRADD also has been reported to
have an effect in promoting cell death. The lack of cell death in
TRADD-silenced cells was confirmed by an Annexin-FACS assay
(Figure 5C). Thus, the prosurvival role of TRADD appears to domi-
nate in glioma cells.
Temozolomide is a first-line chemotherapeutic drug in GBM and
is administered as the standard of care to patients with GBM. We
examined whether the presence of TRADD influenced the effect of
temozolomide on the viability of U251MG glioma cells in TRADD-
silenced cells (clone 26) compared to control shRNA cells. As can be
seen in Figure 5D, U251 control shRNA cells are somewhat resistant
to the effect to temozolomide. However, silencing TRADD results
in a significantly decreased viability of U251 cells in response to
temozolomide. These findings are consistent with a prosurvival role
of TRADD in glioma cells and also with our finding that increased
TRADD levels result in a worse PFS in GBMs, possibly by conferring
resistance to treatment with temozolomide.
The Role of TRADD in Glioma-Initiating Stem-Like Cells
While established GBM cell lines provide an isogenic and widely
used experimental model for glioma studies, glioma-initiating stem-like
cells derived from human GBM samples and cultured as neurospheres
in defined medium resemble primary GBMs more closely compared
to established GBM cell lines [36]. Thus, we examined a panel of
primary GBM cultures grown as neurospheres for the presence of
TRADD. TRADD can be detected in neurosphere cultures derived
from all GBM tumors (Figure 6A). Next, we silenced TRADD
in glioma stem-like cultures derived from GBM tumor 836. Two
TRADD-silenced pools were generated with better silencing of
TRADD in pool 2 (Figure 6B). We conducted an Annexin-FACS
assay to determine the effect of TRADD silencing in TRADD pool
2 compared to control shRNA cells. Interestingly, silencing TRADD
resulted in a sharp drop in viability of these stem-like cultures with
a large increase in Annexin-positive cells as shown in Figure 6C .
A similar result was obtained in GBM622 as shown in Figure 6D.
Silencing of TRADD in GBM622 is shown in Figure 6E . In
addition, we confirmed that TRADD silencing results in impaired
NF-κB activation by comparing phosphorylation of the p65 subunit
of NF-κB, reporter assays, and induction of an NF-κB target
gene (IL-8; Figure 7, A–C ). These findings demonstrate a require-
ment for TRADD in NF-κB activation and maintenance of GBM
stem cell populations and are consistent with a previous study that
revealed a role for NF-κB in the maintenance of glioma stem-like
cultures [37].
Discussion
While TRADD has been investigated extensively in inflammation and
immune signaling, relatively little is known about its role in cancer.
TRADD belongs to the TNF receptor superfamily, whose members
may influence survival or cell death depending on the cellular context.
It is well established that TRADD has a role in NF-κB activation and
promotion of cell survival. Aberrant NF-κB activation is widespread
in cancer and promotes the malignant phenotype and resistance
Table 1. Multivariate Cox Regression Analysis of the Cytoplasmic TRADD Level and Clinical
Variables in GBM Patients.
HR 95% CI P
IHC levels
High versus low 2.471 1.143 5.341 .021
Age 0.970 0.929 1.012 .159
Gender
Male versus female 0.544 0.228 1.298 .170
KPS 0.956 0.908 1.007 .090
Surgery
PR versus CR 1.454 0.422 5.005 .553
CR indicates complete response; PR, partial response.
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Figure 4. (A) U251MG cells were infected with control (scrambled) lentivirus or with TRADD shRNA lentivirus, followed by puromycin
selection and Western blot of clones infected with TRADD shRNA. Clones 15 and 26 show the best silencing of TRADD. (B) Degrada-
tion of IκBα in response to TNF-α (20 ng/ml) can be seen in U251MG control shRNA cells, showing that TNF-α activates NF-κB in
these cells. (C and D) Failure of IκBα degradation in response to TNF-α in TRADD-silenced clones 15 and 26, demonstrating that TRADD
is essential for NF-κB activation. (E) A reporter assay in clone 26 with an NF-κB responsive luciferase reporter. While NF-κB transcrip-
tional activity increases in response to TNF-α in control shRNA cells, there is no increase in TRADD-silenced clone 26, again confirm-
ing the requirement for TRADD in NF-κB activation (one-way ANOVA, P = .0031). (F) Western blot showing that phosphorylation of the
p65 subunit of NF-κB is in response to TNF-α is impaired in TRADD-silenced clone 26. (G) Quantitative real-time polymerase chain
reaction experiment showing that mRNA levels of the NF-κB target gene IL-8 is decreased in TRADD-silenced clone 26, both at a basal
level (P ≤ .0001) and in response to TNF-α (P ≤ .0001) compared to control. Newman-Keuls multiple comparison test was used for
statistical analysis.
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to treatment. The mechanisms of NF-κB activation in cancer are
diverse but may include overexpression of individual components of
the NF-κB signaling network. In GBM, NF-κB activation is well
documented and a focus of considerable investigation. It has been pos-
tulated that the major mechanisms of NF-κB activation in GBM are
aberrant EGFR signaling and deletion of NFKBIA (which encodes
IκBα) is commonly deleted in non–EGFR-amplified GBMs resulting
in NF-κB activation [26–29].
However, data from The Cancer Genome Atlas have docu-
mented that increased expression of components of the NF-κB
Figure 5. (A) An MTT conversion assay was conducted comparing U251 cells with control shRNA or stably silenced TRADD (clones 15
and 26). MTT conversion is higher in control cells compared to TRADD-silenced cells suggesting increased proliferation in control cells
(one-way ANOVA, P = .005). Cell death was excluded by trypan blue exclusion in parallel experiments. (B) Analysis of cell proliferation
in U251 TRADD-silenced and control shRNA clones. 5K cells were plated onto 24-well dishes for 72 hours followed by trypsinization and
counting in an automated cell counter. Cell proliferation is decreased in TRADD-silenced clones 15 and 26 (one-way ANOVA, P = .04).
(C) An Annexin-FACS assay was conducted to determine if TRADD silencing leads to cell death. The percentage of viable cells was
compared in control and TRADD-silenced cells by unpaired t test. No cell death was detected in TRADD-silenced clone 26. (D) An
MTT conversion assay was conducted in U251 cells with control shRNA or TRADD-silenced clone 26 to assess the response to in-
creasing doses of temozolomide. While U251 control shRNA cells are somewhat resistant to temozolomide, silencing TRADD increases
the vulnerability of cells to temozolomide at 10 μM (P≤ .04), 25 μM (P≤ .04), and 50 μM (P≤ .0003) in comparison to the control shRNA
cells. Data were analyzed by two-tailed unpaired t test.
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signaling network including TRADD and RelB can be detected in
the mesenchymal subtype of GBMs. Since it is known that over-
expression of TRADD is sufficient to activate NF-κB in vitro [1],
increased expression of TRADD at the protein level may be suf-
ficient to activate NF-κB in GBMs. Furthermore, our findings
that increased TRADD expression is common in GBM suggest
that TRADD-mediated activation of NF-κB may be an important
mechanism in GBM. Furthermore, TRADD overexpression may
cooperate with other mechanisms such as deletion of NFKBIA to
activate NF-κB.
TRADD can be detected in both cytoplasmic and nuclear compart-
ments. The major function of cytoplasmic TRADD is likely to be
NF-κB activation in response to extrinsic stimuli. Our data suggest
that high levels of cytoplasmic TRADD confer a worse prognosis,
in terms of PFS in GBM, a finding that is valid both in univariate
and multivariate analyses, demonstrating that cytoplasmic TRADD
Figure 6. (A) A panel of glioma stem-like cultures grown as neurospheres from various GBMs was screened for the presence of TRADD by
Western blot. All of the stem cell cultures express TRADD. (B) TRADD was silenced in neurosphere culture derived from GBM836 using
lentiviral shRNA followed by puromycin selection, and two pools were examined. Pool 2 has better silencing of TRADD. Control shRNA
(scrambled) cells were used as control. (C) While themajority of control shRNA cells are viable, silencing TRADD in glioma stem cell cultures
results in cell death with increased Annexin-positive cells (P ≤ .008, two-tailed unpaired t test). (D) A second GBM primary neurosphere
culture from GBM622 with silenced TRADD also shows increased Annexin-positive cells in TRADD-silenced cells compared to control
shRNA cells (P ≤ .0006, two-tailed unpaired t test). (E) Western blot showing silencing of TRADD in GBM622 neurosphere cultures.
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confers a worse PFS in GBM. PFS is an indicator of responsiveness to
treatment. Thus, it is likely that high levels of cytoplasmic TRADD
inhibit sensitivity to chemotherapeutic drugs such as temozolomide.
This hypothesis is supported by our experimental data showing that
silencing TRADD increases sensitivity to temozolomide in glioma cells.
The TRADD-mediated resistance to temozolomide is presumably
secondary to increased NF-κB activation driven by increased levels of
cytoplasmic TRADD. Increased levels of TRADD did not influence
OS, consistent with the devastating and intractable nature of GBM.
Less is known about nuclear TRADD, and in our analysis, nuclear
TRADD did not influence prognosis. However, nuclear TRADD
may play an important role in regulating apoptosis and have a tumor
suppressive influence in other cancers. A recent study has proposed that
nuclear TRADD promotes p19Arf stability and tumor suppression [8].
TRADD has also been reported to form a complex with STAT-1 in
the nucleus [9]. Thus, emerging evidence suggests that TRADD may
have complex roles in cancer depending on the tumor type and micro-
environment of the tumor. However, our data indicate that increased
cytoplasmic TRADD plays an oncogenic role in GBM.
The oncogenic role of TRADD in GBM is likely related to the role
of TRADD in NF-κB activation. In addition to its well-known role in
inflammation, NF-κB activation also influences cell survival, cell cycle
progression, and proliferation. Indeed, there is an extensive cross talk
between NF-κB components and growth factor signaling and cell
cycle pathways [38–43]. Activation of NF-κB also regulates cell cycle
progression and cell proliferation by mechanisms that include the
expression of cytokines that promote proliferation of tumor cells [44–
46] and by inducing expression of cyclin D1 and c-Myc [47,48]. In
our experiments, silencing TRADD resulted in decreased NF-κB acti-
vation and decreased proliferation of glioma cells. Importantly, silencing
TRADD increased the susceptibility of glioma cells to temozolomide,
consistent with the effect of TRADD on PFS. Another intriguing find-
ing of this study is expression of TRADD in glioma stem-like cultures
derived from primary GBMs. We detected TRADD in all of the stem-
like cultures we tested. Importantly, silencing TRADD in GBM stem
cell cultures inhibited NF-κB activation and sharply reduced the viabil-
ity of cells indicating a requirement for TRADD in maintaining stem
cell cultures. Our findings are consistent with a previous study that
revealed a role for NF-κB in the maintenance of glioma stem-like
cultures [37].
In summary, cytoplasmic expression of TRADD is common in
GBM and adversely influences prognosis, presumably by activation
of NF-κB and conferring resistance to treatment. Experimental loss
of function studies show an important role of TRADD in prolifera-
tion of GBM cells and in conferring resistance to temozolomide. In
GBM stem cell populations, TRADD is commonly expressed and
may be required for maintenance of GBM stem cells. Furthermore,
we propose that TRADD overexpression is an important mechanism
of NF-κB activation in GBM. Thus, TRADD plays an oncogenic
role in GBM and may be an important biomarker as well as an
attractive target for therapeutic intervention in this disease.
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